Tizona Therapeutics
PrivateLast Round
Corporate Funding
Jul 21, 2020
Est. Valuation
$601.2M
Total Funding Raised
$475M
Company Overview
Tizona Therapeutics is a biotechnology company that develops first-in-class immunotherapies to treat cancer and autoimmune diseases by modulating immunosuppressive cell activity in the tumor microenvironment.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tizona Therapeutics Comparables
Compare Tizona Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Trishula Therapeutics | 92% | |
| Immune-Onc Therapeutics | 84% | |
| OncoResponse | 81% |
Tizona Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Jul 21, 2020 | ||||
| Strategic | Jan 3, 2019 | ||||
| Series B | Mar 8, 2016 | ||||
| Series A | Jan 1, 2016 |
Key People
Founding team and executive leadership
Tizona Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MPM Capital | Series B |
| InterWest Partners | Series B, Series A |
| Lightstone Ventures | Series B |
| MPM BioImpact | Series B, Series A |
| Amgen Ventures | Series B, Series A |
| Abingworth | Series B |
| Canaan Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 3, 2019
$105M round led by AbbVie and Astellas Venture Management.
- Mar 8, 2016
$43M round led by Canaan Partners and Abingworth.
Tizona Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Tizona Therapeutics's valuation, stock price, and market status.
Is Tizona Therapeutics a public or private company?
Tizona Therapeutics is a private company.
What is the current stock price of Tizona Therapeutics?
Tizona Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Tizona Therapeutics worth (valuation)?
Tizona Therapeutics's valuation is estimated at $601.2M based on funding round data.
Can I buy Tizona Therapeutics stock?
Tizona Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Tizona Therapeutics's last funding round?
Tizona Therapeutics's most recent funding round was Strategic on July 21, 2020.
Who are the main investors in Tizona Therapeutics?
Key investors in Tizona Therapeutics include Abingworth, Canaan Partners.
Will Tizona Therapeutics IPO soon?
No public IPO plans have been announced for Tizona Therapeutics.
How can I track Tizona Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Tizona Therapeutics's secondary market activity and sign up for updates.